A Clinical Guide to Smoking Cessation
Evidence-based pharmacotherapy, behavioral interventions, and support systems for helping patients quit
Tobacco dependence is a chronic disease that often requires repeated interventions and multiple quit attempts. While over 70% of people who smoke want to quit, unaided attempts β going "cold turkey" without any support β have a meager success rate of around 5%, with 65% relapsing within a year. Combining evidence-based pharmacotherapy with behavioral support and structured follow-up dramatically improves these odds.
1. The Clinical Baseline: The 5 A's Model
Brief clinical interventions are highly effective. The U.S. Public Health Service recommends the 5 A's framework for every patient encounter where tobacco use is present.
2. The Pharmacotherapy Arsenal
First-line, FDA-approved pharmacotherapies work by mitigating nicotine withdrawal and blocking the reinforcing effects of smoking. Estimated 12-week continuous abstinence rates vary substantially by treatment choice.
Estimated 12-week continuous abstinence rates by treatment. Rates are approximate and vary across trials and patient populations.
Varenicline (Chantix)
Varenicline is a partial agonist with high selectivity for Ξ±4Ξ²2 nicotinic acetylcholine receptors. It blocks nicotine from binding while providing enough receptor stimulation to reduce withdrawal symptoms and cravings. Multiple meta-analyses and the landmark EAGLES trial demonstrate that varenicline is significantly more effective at maintaining continuous abstinence at 12, 24, and 52 weeks compared to bupropion, NRT alone, and placebo.
Importantly, the EAGLES trial confirmed that varenicline does not increase the risk of adverse neuropsychiatric events, even in patients with psychiatric disorders β a concern that had previously limited its use in this population.
Bupropion SR (Zyban)
Originally developed as an atypical antidepressant, bupropion acts as a norepinephrine and dopamine reuptake inhibitor and also functions as an antagonist at nicotinic acetylcholine receptors. It roughly doubles abstinence rates compared to placebo and is particularly useful for patients with comorbid depressive symptoms or those concerned about post-cessation weight gain.
Nicotine Replacement Therapy (NRT)
NRT increases the chance of quitting by approximately 55% compared to placebo. It relies on slow systemic venous absorption rather than the rapid arterial spikes of inhaled cigarette smoke, substantially reducing the addictive "hit." Available formulations include the transdermal patch (long-acting), and gum, lozenge, inhaler, and nasal spray (short-acting).
Cytisine, a partial agonist pharmacologically similar to varenicline, is highly effective and far more affordable but is currently only available in Central and Eastern Europe and lacks FDA approval. Nicotine vaccines β designed to generate antibodies that prevent nicotine from crossing the blood-brain barrier β remain in experimental development.
3. The "Cold Turkey" Debate
Many patients prefer to gradually reduce their smoking before quitting entirely. However, the evidence favors the opposite approach. A large randomized non-inferiority trial by Lindson-Hawley et al. found that setting a fixed quit date and stopping abruptly was significantly more effective than gradual reduction β even among patients who expressed a preference for gradual reduction.
Setting a firm quit date and stopping completely. More effective regardless of patient preference. Supports psychological commitment and avoids prolonging cue exposure.
Progressively reducing cigarettes before a quit date. Lower success rates even among patients who preferred this method. May perpetuate cue-reactivity and nicotine dependence.
Source: Lindson-Hawley N, et al. Gradual versus abrupt smoking cessation: a randomized, controlled noninferiority trial. Ann Intern Med. 2016;164(9):585β592.
4. Psychological Therapies
Pharmacotherapy works best when paired with behavioral support. Several evidence-based psychological approaches improve quit rates by addressing the cognitive, emotional, and habitual dimensions of tobacco dependence.
Cognitive Behavioral Therapy helps patients identify triggers, develop coping strategies, and manage negative affect. Motivational interviewing, combined with behavioral support, shows significant benefits over brief advice alone in systematic reviews. Together they address the psychological core of habit and relapse.
Research from Stanford's Dr. David Spiegel shows that a single structured clinical hypnosis session can yield a 23% success rate for smoking cessation β comparable to pharmacotherapy. The Reveri app delivers validated hypnosis protocols developed at Stanford and is widely accessible to patients as a low-barrier option.
Acceptance and Commitment Therapy (ACT), distress tolerance skills, and mindfulness-based approaches teach patients to observe cravings and negative affect without automatically reacting to them. While Cochrane reviews find no clear long-term benefit for general mindfulness training over matched-intensity standard treatments, ACT delivered via smartphone app (e.g., iCanQuit) has shown a significant benefit over standard cessation apps.
5. Support Systems and Treatment Extenders
Connecting patients to support infrastructure beyond the clinical visit substantially improves long-term outcomes. These resources are free, evidence-based, and require minimal clinician time to implement.
State Quitlines (1-800-QUIT-NOW)
Quitlines offer evidence-based coaching and often provide free NRT. They increase quit rates by approximately 60% compared to minimal counseling. Highly cost-effective and available to any patient with a phone. A warm handoff β directly connecting the patient to the quitline during the visit β drastically increases engagement compared to simply providing a pamphlet.
EHR eReferrals & Warm Handoffs
Utilizing electronic health record eReferral systems to directly connect patients to quitlines can increase referral rates 3-to-6-fold compared to passive handoffs. A structured workflow β where clinical staff complete the referral during the encounter β ensures patients are connected before leaving the office, dramatically improving follow-through.
Digital Health Resources
Encourage patients to use free digital resources available today: the quitSTART app (CDC-developed), smokefree.gov with personalized quit plans, and the National Texting Portal (Text QUITNOW to 333888). For evidence-based third-generation therapy, the iCanQuit app (ACT-based) and Reveri (clinical hypnosis) are both supported by published trial data.
6. Clinical Summary
Key Recommendations for Maximizing Quit Success
- Use the 5 A's framework at every encounter β even brief advice increases quit attempts and sets the stage for intervention.
- Prescribe varenicline as first-line when there are no contraindications; it outperforms bupropion and NRT monotherapy in head-to-head trials including in patients with psychiatric illness (EAGLES).
- Use combination NRT (patch + short-acting formulation) when varenicline is not preferred or tolerated; it significantly outperforms single-formulation NRT.
- Recommend an abrupt quit date β the evidence favors stopping cold turkey over gradual reduction, even for patients who prefer the latter.
- Provide a warm handoff to a state quitline (1-800-QUIT-NOW) or an evidence-based digital platform (iCanQuit for ACT, Reveri for clinical hypnosis) before the patient leaves your office.
- Arrange follow-up within the first week post-quit date. Relapse is most likely in the first days and weeks, and timely contact is associated with sustained abstinence.
- U.S. Public Health Service. USPHS Clinical Practice Guideline: Treating Tobacco Use and Dependence Overview of Best Practice Recommendations. 2008.
- Anthenelli RM, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES). Lancet. 2016;387(10037):2507β2520.
- Patel AR, Panchal JR, Desai CK. Efficacy of Varenicline versus Bupropion for Smoking Cessation. Indian J Psychiatry. 2023;65(5):526β533.
- Lindson-Hawley N, et al. Gradual versus abrupt smoking cessation: a randomized, controlled noninferiority trial. Ann Intern Med. 2016;164(9):585β592.
- GarcΓa-GΓ³mez L, et al. Smoking Cessation Treatments: Current Psychological and Pharmacological Options. Rev Invest Clin. 2019;71:7β16.
- Jackson S, et al. Mindfulness for Smoking Cessation. Cochrane Database Syst Rev. 2022;4:CD013696.
- Fiore MC, Baker TB. 10 Million Calls and Counting: Progress and Promise of Tobacco Quitlines. Am J Prev Med. 2021;60(3 Suppl 2):S103βS106.
- Smith DK, Miller DE, Mounsey A. 'Cold Turkey' Works Best for Smoking Cessation. J Fam Pract. 2017;66(3):174β176.
- Rahimi F, Massoudifar A, Rahimi R. Smoking Cessation Pharmacotherapy: Varenicline or Bupropion? DARU J Pharm Sci. 2024;32:901β906.
- Centers for Disease Control and Prevention. 1-800-QUIT-NOW: 15 Years of Helping People Quit. 2019.